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Objectives: To determine the expression status of several proteins related to VHL gene function and its relationship with common
clinicopathological parameters.
Material and methods: Observational, analytical, cross-sectional study with 50 patients diagnosed with clear cell renal cell carcinoma.
The study analyzed VHL mutations and hypermethylation as well as protein expression of VHL, CA-IX, HIF-1alpha, VEGF, ERK1/2, and
ERK5, relating them to clinical variables.
A bivariate and multivariate descriptive logistical regression analysis was performed, using the presence of metastasis at diagnosis as
dependent variable.
Results: The study identiﬁed 13 (26%) VHL mutations related to nuclear grade (P ¼ 0.036). VHL hypermethylation was found in 20%
of cases. VHL expression was associated with the presence of mutations (P ¼ 0.013), and the absence of expression was associated with
nuclear grade and the presence of metastasis (Po 0.05). HIF-1alpha was negative in only 5 cases. Vascular endothelial growth factor
(VEGF) was positive in 31 of 47 cases and was associated with Fuhrman nuclear grade, presence of metastasis, and stage (Po 0.05). ERK5
expression was increased in 58% of cases and associated with the presence of metastasis and more advanced stages (Po 0.05). In the
logistic regression analysis, the only variable remaining in the model was VEGF expression (P ¼ 0.014).
Conclusions: VEGF has prognostic value in clear cell renal cell carcinoma, and ERK5 may be a new prognostic marker in this type of
tumor owing to its relationship with metastasis and more advanced stages. r 2016 Elsevier Inc. All rights reserved.
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Renal tumors account for 3% of all neoplasms, and renal
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m@sescam.jccm.es (J.M. Giménez-Bachs).adult kidney. Various molecular abnormalities characterize
the different subtypes of this neoplasm, making them
different from each other and giving them various properties
which can affect therapeutic response or prognosis [1].
VHL gene abnormalities are a known factor in clear cell
renal cell carcinoma (ccRCC). Both the gene and its protein
have tumor suppressor function, but this is based on a series of
molecular mechanisms involving other proteins, which will
initiate their activity depending on the amount of oxygen in the
environment and on VHL functionality itself [2].
Therefore, certain molecular and environmental states
will activate several proteins, such as carbonic anhydrase-IX
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hypoxia. Another is hypoxia-inducible factor 1-alpha (HIF-
1alpha), which mediates metabolic adaptation according to
available oxygen and can transactivate other genes with
protein products that increase oxygen uptake. Yet another
protein is vascular endothelial growth factor (VEGF),
related to neoangiogenesis. Likewise, the mitogen-
activated protein kinase (MAPK) family may also play a
key role in the molecular cascade activated when clear cell
renal tumor genesis begins, in many cases fostered by VHL
malfunction [3].
The aim of this study was to characterize the molecular
state of a ccRCC series to better understand the behavior of
this type of tumor and to determine if molecular abnormal-
ities more clearly explain patient prognosis or if certain
characteristics will aid the molecular diagnosis or therapeu-
tic approaches taken.2. Subjects, material, and method
The study was based on an observational, analytical, and
cross-sectional design with 50 patients diagnosed with
ccRCC between 2006 and 2011 and treated surgically.
Tumor tissue specimens and healthy renal tissue (con-
trol) were collected and stored at 801C, and the following
techniques were used for molecular analysis of the samples:(1) VHL gene mutational and methylation analysis:
Genomic DNA was extracted using the QIAamp
DNA kit (QIAGEN). The polymerase chain reaction
primers and conditions for VHL gene sequencing were
those used by Patard et al. [4]. Mutations were
determined via automatic DNA sequencing by capillary
electrophoresis in both directions of the gene, such that
only abnormalities detected in both sequencing direc-
tions in the electrophoretogram were considered muta-
tions. The control group consisted of polymerase chain
reaction products obtained from DNA taken from
healthy renal parenchyma.
Sodium bisulphite conversion with 1 μg of genomic
DNA was performed using an EZ-96 DNA Methylation
kit (Zymo Research) according to the manufacturer’s
protocol and the alternative conversion protocol
(a 2-temperature DNA denaturation) designed by Seque-
nom. Sequenom’s MassARRAY platform was used to
perform quantitative methylation analysis. EpiTYPER
methylation was performed by the Medical Research
Department of the Central Research Unit (ICU) at the
University of Valencia. Tumor specimens with at least 10
of 41 methylated CpGs (26%) were considered as hyper-
methylated [5]. The Caki-2 and 769-P cell lines were used
as positive and negative controls with nonmethylated and
methylated VHL promoter, respectively [6].(2) Western blot: Samples were processed and quantiﬁed as
previously described [7]. Then 100 μg (extracellularsignal-regulated kinase 5 [ERK5]) or 50 μg (CA-IX and
ERK1/2) were loaded onto 6% or 10% sodium dodecyl
sulfate-polyacrylamide gel electrophoresis, transferred to
polyvinylidene ﬂuoride ﬁlters and blotted against differ-
ent proteins using speciﬁc antibodies. Antibody detec-
tion was achieved by enhanced chemiluminescence
(ECL, Amersham). Antibodies used were CA-IX
(CA-IX Antibody H-120; 1:1000 in 0.5% bovine serum
albumin [BSA] in Tris-buffered saline [T-TBS], Santa
Cruz Biotechnology), ERK5 (1:1000 in 5% BSA in
T-TBS, Cell Signaling); ERK1/2 (1:1000 in 5% BSA in
T-TBS, Santa Cruz Biotechnology) as loading control
membranes were reproved against Tubulin (1:3000 in
5% milk in T-TBS, Santa Cruz Biotechnology).(3) Immunohistochemistry: This technique was used to
determine protein expression in the case of CA-IX,
VHL, HIF-1alpha, and VEGF. All cases were reviewed
and diagnosed according to the criteria of the World
Health Organization classiﬁcation [8] in the Pathology
Department of our center. Parafﬁn blocks were available
in all cases. Formalin-ﬁxed parafﬁn-embedded tissue
sections of 4 mm were cut, deparafﬁnized in xylene and
rehydrated in a graded series of ethanol. Endogenous
peroxidase was blocked with 3% H2O2 for 5 minutes.
Slides were treated with heat-induced epitope retrieval
and immunostained with monoclonal rabbit antibody
CA-IX in 1:1500 dilution (Abcam); VHL in 1:200
dilution (BD Pharmingen); HIF-1alpha in 1:200 dilution
(Novus); and VEGF in 1:400 dilution (Dako) and
detected using the EnVision system-HRP (Dako)
according to the manufacturer’s instructions.Immunohistochemical staining was done by a single
pathologist blinded to the clinicopathologic variables.
Tumor cells were scored as strong (þ3), moderate (þ2),
weak (þ1) (all considered to be positive expression in
further analyses), and negative CA-IX expression.
The statistical analysis evaluated the presence of VHL
gene mutations and the site and type of mutation. Addi-
tionally, the presence of VHL gene hypermethylation and
the presence of expression (according to criteria described
earlier) were analyzed by western blot or immunohisto-
chemistry of the VHL, CA-IX, HIF-1alpha, VEGF, ERK5,
and ERK1/2 proteins. Patient data were collected for
sociodemographic and clinical variables, as well as Fuhr-
man nuclear grade and tumor stage according to the TNM
classiﬁcation [8]. A descriptive analysis and a bivariate
analysis were performed by independence tests (Pearson χ2i ,
linear trend, Student t-test, and analysis of variance)
applying their respective nonparametric tests in the cases
indicated. A multivariate logistic regression analysis was
performed using the presence of metastasis at the time of
diagnosis as a dependent variable and the other independent
variables as covariables, estimating the respective regression
coefﬁcients. Because this was a cross-sectional study, the
ORs obtained are understood to be of prevalence.
Table 1
Clinicopathological characteristics of the patients
N %
Sex
Male 34 68
Female 16 32
Clinical symptoms
Incidental 19 38
Nonincidental 31 62
Fuhrman nuclear grade
1 4 8
2 21 42
3 14 28
4 11 22
T stage
pT1a 9 18
pT1b 13 26
pT2 13 26
pT3a 8 16
pT3b 7 14
M stage
M1 19 38
Mx or M0 31 62
TNM
I 19 38
II 10 20
III 2 4
IV 19 38
Table 3
Correlation between VHL gene mutation and protein expression by
immunohistochemistry
VHL mutation VHL expression by immunohistochemistry P
None to low Moderate to high Total
No, N 17 20 37 0.013
% 94.4 62.5 74
Yes, N 1 12 13
% 5.6 37.5 26
Total, N 18 32 50
% 100 100 100
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Mean patient age was 62.2 years (standard deviation ¼
11.9), and 68% were men, giving a male-to-female ratio of
2:1. There were no signiﬁcant age- or sex-related differences.Table 2
Relationship between mutations and clinical characteristics of the patients
Site Codon Type Fuhrman
nuclear
grade
pT pM TNM
Exon 2 136 Deletion (1) (A) 3 pT1b pMx I
Exon 1 88 Point (C ) T) 1 pT1b pMx I
Exon 2 137 Insertion (þ1) (þT) 2 pT2 pM0 II
Exon 1 112 Insertion (þ1) (þA) 2 pT3a pM1 IV
Intronic Point (C ) A) 4 pT3b pM1 IV
Exon 2 128 Insertion (þ1) (þC) 2 pT1b pM0 I
Exon 3 175 Insertion (þ1) (þT) 1 pT1a pM0 I
Exon 1 78 Point (G ) T) 2 pT1b pM0 I
Exon 1 54 Deletion (11) 4 pT1b pM1 IV
Exon 1 62 Deletion (2) (TG) 1 pT3a pMx III
Exon 3 176 Deletion (3)
(AGG)
2 pT3a pMx III
Exon 1 107 Deletion (1)
(del C)
2 pT1a pM0 I
Exon 1 88 Point (A ) G) 2 pT2 pM1 IVIn the histological study, the most common Fuhrman
nuclear grade was grade 2 in 42% of cases, followed by
grade 3 in 28%, and grade 4 in 22%. TNM stage was I in
38% of cases and IV in another 38% of cases. The
clinicopathological characteristics are listed in Table 1.
All tumors were positive for the CA-IX protein by
immunohistochemistry, but were negative in 2 cases by
western blot.
VHL gene sequencing found 13 mutations in 13 (26%)
patients. No statistically signiﬁcant relationship was found
between the presence of mutations and the usual clinicopa-
thological parameters (sex, age, and stage) except for
Fuhrman nuclear grade, as mutations were mainly detected
in grade 2 tumors (P ¼ 0.036). The remaining character-
istics of the mutations are listed in Table 2, which shows
that most were detected at exon 1 and only 1 in intron
position.
The VHL gene methylation study revealed hypermethy-
lation in 10 (20%) cases, but the determination was
impossible in 4 (8%) patients. An association was only
found between promoter methylation state and clinical
picture, with this association being more common in
patients who showed clinical symptoms at the time of
diagnosis than in those diagnosed incidentally (P ¼ 0.008).
Although not statistically correlated, patients with distant
metastases were more likely to have hypermethylation (20%
vs. 8%).
When VHL protein expression was measured by
immunohistochemistry, 32 (64%) cases showed
moderate-to-high expression, which was associated with
the presence of mutations, as shown in Table 3
(P ¼ 0.013). VHL nonexpression correlated with higher
Fuhrman grades (P ¼ 0.001) and the presence of distant
metastasis (P o 0.05). There was no signiﬁcant relation-
ship between clinicopathological factors (nuclear grade,
pT, pN, pM, or TNM) and VHL expression in tumors
with no mutation.
The correlations between VHL gene mutations, VHL
gene hypermethylation, and VHL protein expression and
the pathological factors are summarized in Table 4.
HIF-1alpha expression by immunohistochemistry was
seen in most samples, although at differing degrees of
intensity (Figure 1). Only 5 cases showed no expression of
Table 4
VHL status (gene and protein) and correlation with clinical parameters
VHL gene mutation VHL gene hypermethylation VHL protein expression
No, N (%) Yes, N (%) P No, N (%) Yes, N (%) P None to low, N (%) Moderate to high, N (%) P
Fuhrman nuclear grade
1 1 (25) 3 (75) 0.036 4(100) 0 (0) ns 0 (0) 4 (100) 0.023
2 14 (66.7) 7 (33.3) 19 (95) 1(5) 6 (28.6) 15 (71.4)
3 13 (92.9) 1 (7.1) 9 (64.3) 5 (35.7) 4 (8.6) 10 (71.4)
4 9 (81.8) 2 (18.2) 8 (62.5) 3 (37.5) 8 (72.7) 3 (27.3)
pT stage
pT1a 7 (77.8) 2 (22.2) ns 9 (88.9) 1 (11.1) ns 2 (22.2) 7 (77.8) ns
pT1b 8 (61.5) 5 (38.5) 11 (81.8) 2 (18.2) 5 (38.5) 8 (61.5)
pT2 11 (84.6) 2 (15.4) 12 (92.3) 1 (7.7) 4 (30.8) 9 (69.2)
pT3a 5 (62.5) 3 (37.5) 5 (71.4) 2 (28.6) 2 (25) 6 (75)
pT3b 6 (85.7) 1 (14.3) 3 (50) 3(50) 5 (71.4) 2 (28.6)
pM stage
pMx 10 (71.4) 4 (28.6) ns 13 (100) 0 (0) ns 4 (28.6) 10 (71.4) ns
pM0 12 (70.6) 5 (29.4) 13 (81.3) 3 (18.7) 5 (29.4) 12 (70.6)
pM1 15 (78.9) 4 (21.1) 11 (64.7) 6 (35.3) 9 (47.4) 10 (52.6)
TNM stage
I 13 (68.4) 6 (31.6) ns 15 (88.2) 2 (11.8) ns 5 (26.3) 14(73.7) ns
II 9 (90) 1 (10) 9 (90) 1(10) 4 (40) 6 (60)
III 0 (0) 2 (100) 2 (100) 0 (0) 0 (0) 2 (100)
IV 15 (78.9) 4 (21.1) 11 (64.7) 6 (35.3) 9 (47.4) 10 (52.6)
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are shown in Table 5.
VEGF expression was positive in 31 of 47 cases
analyzed for this protein. No correlation was found betweenFig. 1. HIF-1alpha expression by immunohistochemistry: (A) severe (þ3); (B) m
available online.)the expression of this protein and clinical parameters,
although there was a correlation with pathological param-
eters, such as Fuhrman nuclear grade, presence of meta-
stasis, and TNM stage (Table 6) (p o 0.05). However,oderate (þ2), (C) mild (þ1); and (D) negative. (Color version of ﬁgure is
Table 5
HIF-1alpha and clinicopathological factors
HIF-1alpha by inmunohistochemistry P
Negative o10% cells 10%–50% cells 450% cells Total
Frec. % Frec. % Frec. % Frec. % Frec. %
Fuhrman nuclear grade
Grades 1 and 2 0 0 3 33.3 4 50 18 72 25 53.2 0.014
Grades 3 and 4 5 100 6 66.7 4 50 7 28 22 46.8
Total 5 100 9 100 8 100 25 100 47 100
pT stage
pT1a 0 0 1 11.1 2 25 6 24 9 19.1 ns
pT1b 1 20 2 22.2 1 12.5 8 32 12 25.5
pT2 3 60 3 33.3 1 12.5 6 24 13 27.7
pT3a 0 0 1 11.1 2 25 4 16 7 14.9
pT3b 1 20 2 22.2 2 25 1 4 6 12.8
Total 5 100 9 100 8 100 25 100 47 100
pN stage
pNx 4 80 7 77.8 8 100 22 88 41 87.2 ns
pN0 1 20 2 22.2 0 0 3 12 6 12.8
Total 5 100 9 100 8 100 25 100 47 100
pM stage
pMx 1 20 1 11.1 2 25 9 36 13 27.7 ns
pM0 1 20 3 33.3 2 25 11 44 17 36.2
pM1 3 60 5 55.6 4 50 5 20 17 36.2
Total 5 100 9 100 8 100 25 100 47 100
TNM stage
I 0 0 2 22.2 3 37.5 13 52 18 38.3 ns
II 2 40 2 22.2 1 12.5 5 20 10 21.3
III 0 0 0 0 0 0 2 8 2 4.3
IV 3 60 5 55.6 4 50 5 20 17 36.2
Total 5 100 9 100 8 100 25 100 47 100
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VHL abnormality because of either methylation or the
presence of mutations.
ERK5 expression was evaluated by western blot
(Figure 2) and compared with the control sample from
healthy parenchyma, with increased expression found in
58% of cases, whereas the rest showed equal or lower
expression than the respective control. The presence of
distant metastases and more advanced stage was signiﬁ-
cantly related to ERK5 overexpression (Po 0.05) but not
with other clinicopathological parameters analyzed
(Table 7). All tumors not expressing VHL by immunohis-
tochemistry did overexpress ERK5 (P ¼ 0.009), whereas
promoter methylation abnormalities or the presence of VHL
gene mutations were not related to ERK5 expression. ERK5
expression was stronger in 21 of 31 cases that overex-
pressed VEGF (P ¼ 0.017).
There were no differences in ERK1/2 expression between
tumor samples and healthy control 47 of cases presented
similar expression and only 3 overexpressed this protein.
When logistic regression analysis was used to evaluate
the effect of various independent variables on the presenceof distant metastases at the time of diagnosis, the only
variable remaining in the model was VEGF expression.
Consequently, the presence of metastasis in patients with
ccRCC was 8.27-fold (CI: 1.53–44.62) in patients who
overexpress VEGF than in those with no overexpression
(P ¼ 0.014). The power of explanation of the model is
23.9% (Nagelkerke’s R2 ¼ 0.239).4. Discussion
The aim of this study was to establish the molecular
state of the VHL-mediated pathway in a series of clear cell
renal tumors. To do so, the status of various proteins
involved in the molecular pathway of the VHL gene and
protein was determined by western blot or immunohisto-
chemistry.
CA-IX protein expression in this type of tumor appears to be
constant and, therefore, can be considered a characteristic and
exclusive factor of the clear cell subtype. Although it can be
used as a diagnostic marker, its use as a prognostic factor is not
clear and the issue is still under debate; nevertheless,
Table 6
Correlation between VEGF expression status and clinical parameters
VEGF by immunohistochemistry P
Negative Positive Total
N % N % N %
Fuhrman nuclear grade
Grades 1 and 2 12 48 13 52 25 100 0.031
Grades 3 and 4 4 18.2 18 81.8 22 100
Total 16 34 31 66 47 100
pT stage
pT1a 3 33.3 6 66.7 9 100 ns
pT1b 5 41.7 7 58.3 12 100
pT2 6 46.2 7 53.8 13 100
pT3a 2 28.6 5 71.4 7 100
pT3b 0 0 6 100 6 100
Total 16 34 31 66 47 100
pN stage
pNx 14 34.1 27 65.9 41 100 ns
pN0 2 33.3 4 66.7 6 100
Total 16 34 31 66 47 100
pM stage
pMx 5 38.5 8 61.5 13 100 0.037
pM0 9 52.9 8 47.1 17 100
pM1 2 11.8 15 88.2 17 100
Total 16 34 31 66 47 100
TNM stage
I 8 44.4 10 55.6 18 100 0.034
II 4 40 6 60 10 100
III 2 100 0 0 2 100
IV 2 11.8 15 88.2 17 100
Total 16 34 31 66 47 100
Table 7
Correlation between ERK5 expression and clinicopathological factors
ERK5 expression (Western blot) P
Overexpression No expression Total
Frec. % Frec. % Frec. %
Fuhrman nuclear grade
Grades 1 and 2 12 48 13 52 25 100 ns
Grades 3 and 4 17 68 8 32 25 100
Total 29 58 21 42 50 100
pT stage
pT1a 5 55.6 4 44.4 9 100 ns
pT1b 6 46.2 7 53.8 13 100
pT2 7 53.8 6 46.2 13 100
pT3a 5 62.5 3 37.5 8 100
pT3b 6 85.7 1 14.3 7 100
Total 29 58 21 42 50 100
pN stage
pNx 25 56.8 19 43.2 44 100 n.s.
pN0 4 66.7 2 33.3 6 100
Total 29 58 21 42 50 100
pM stage
pMx 8 57.1 6 42.9 14 100 0.03
pM0 6 35.3 11 64.7 17 100
pM1 15 78.9 4 21.1 19 100
Total 29 58 21 42 50 100
TNM stage
I 8 42.1 11 57.9 19 100 0.043
II 6 60 4 40 10 100
III 0 0 2 100 2 100
IV 15 78.9 4 21.1 19 100
Total 29 58 21 42 50 100
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various clinicopathological parameters [9–11].
The VHL gene is known to be altered in ccRCC, but
there are differences according to the study. Gene mutation
levels range from 22% to 57% according to the study
[12–14], and promoter hypermethylation is around 20%
[15,16]. Our study analyzed abnormalities (mutation and
promoter hypermethylation), such that an abnormality in each
or both can lead to inactivation of the gene and its tumor
suppressor activity. However, the fact that these parameters are
not related to those commonly used in clinical practice mayFig. 2. ERK5 protein expression by western blot in a series of ccRCC
tumors. N ¼ tumor specimen; R ¼ healthy renal parenchyma.mean that the VHL gene is altered in early stages of tumor
development and is not related to tumor progression [12].
Immunohistochemistry to investigate VHL protein
expression found that the presence of mutations led to
greater protein expression. This could be explained by
abnormal recognition of the antibody that generates positive
expression (but not necessarily functionality) of the protein
or by a genetic or epigenetic abnormality that affects the
stability of the protein, as described in other proteins that
may have increased half-life and nuclear build-up [17,18].
The fact that the absence of VHL protein expression is
related to higher Fuhrman grades implies a poorer prognosis
for tumors not expressing the protein, an idea reinforced by
a correlation with the presence of distant metastasis,
probably because of loss of the tumor suppressor function
of the VHL protein [19].
If VHL protein abnormalities lead to little or no
HIF-1alpha degradation, the presence of high HIF-1alpha
expression will clearly be common in ccRCC, as occurs in
our series. This ﬁnding is usually present in ccRCC and
makes it difﬁcult to correlate increased expression of this
protein with the clinical parameters because most tumors
overexpress it. Nevertheless, some studies have found
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metastasis [20].
One of the proteins activated by increased expression of
HIF-1alpha is VEGF, a regulator, among other things, of
angiogenesis. Several studies have found that overexpres-
sion of this protein is an adverse prognostic factor that
correlates to the presence of distant metastases or more
advanced stages [21]. In fact, this was the only variable
remaining in the regression model in our study and,
therefore, the protein (end of the VHL-HIF-1alpha pathway)
could be a prognostic biomarker for ccRCC.
MAPK signaling pathways are one the critical mediators
of cell growth and have been related to hypoxia [22].
Indeed, it has been reported a direct control of HIF-1alpha
by several MAPK [23] and in addition ERK5 has been
proposed as a putative target of the VHL signaling axis [7]
known to share biological targets with HIF-1alpha [24].
Regarding ERK5 our data show prominent up-regulation in
tumor samples vs. normal tissue in a high percentage of
ccRCC samples, in agreement with a putative target for
VHL deregulation. However, it is noteworthy that neither
mutational nor methylation studies have shown a correlation
with ERK5 expression. In this regard, several possibilities
can be considered, including other mechanisms to explain
high expression levels of ERK5, for instance deregulated
tyr-kinase activity [25]. However, a relationship has been
found between the ERK5 signaling pathway and the
prognosis of CCRCC [7], as well as other types of tumors
(e.g., colon, breast, or prostate) [26–28], such that increased
expression of this protein is associated with poorer prog-
nosis (more advanced stages and presence of metastasis), as
reported in the current study. Consequently, we can con-
sider that ERK5 expression may be useful as a prognostic
and perhaps therapeutic marker.
This was not the case of ERK1/2, in spite of the high
homolog in the n-terminal region, where no differences
were found in expression between tumor and healthy
parenchyma. Further studies, including a study of these
proteins, are necessary to fully elucidate the role of this
MAPK cascade.
In summary, our analysis of a series of ccRCC tumors
appears to indicate that CA-IX expression is always present
in this cell subtype, that genetic and epigenetic abnormal-
ities do not consistently alter the pattern of protein
expression measured by immunohistochemistry and that
alterations to other proteins (such as HIF-1alpha, VEGF,
and ERK5) appear predominantly, suggesting that they are
implicated in the molecular pathway of the VHL gene, even
though the VEGF protein appears to be the one most
strongly related to prognosis. ERK5 is postulated as a
possible future marker to assess the behavior of this type of
tumor. However, these conclusions should be conﬁrmed by
larger studies that could reveal a pattern of molecular
behavior potentially of use in clinical medicine.
In conclusion, the molecular characterization of tumors
offers considerable possibilities to study tumor genesis anddevelopment as well as the potential response to certain
therapeutic agents.References
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